Heck Capital Advisors’s Gilead Sciences GILD Stock Holding History

Heck Capital Advisors’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-1,093	Closed	-$78.3K	–	76
2016 Q4	$78.3K	Buy	+1,093	New	+$81.2K	0.06%	61

Other funds holding GILD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Parnassus Investments San Francisco, California $34.1B AUM 20.22% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

Heck Capital Advisors's GILD Position: Q1 2017 in Review

Heck Capital Advisors sold out of Gilead Sciences (GILD) in Q1 2017, closing a stake of 1,093 shares — an estimated $78.3K sold.

Heck Capital Advisors first reported a position in GILD in Q4 2016 and held it in 1 quarter. The position peaked at $78.3K in Q4 2016. 1,525 funds tracked by Wall St. Rank hold GILD as of Q1 2017.

Heck Capital Advisors reported no remaining Gilead Sciences position as of Q1 2017 after selling out during the quarter.
Heck Capital Advisors sold 1,093 Gilead Sciences shares in Q1 2017, an estimated $78.3K.
Heck Capital Advisors first reported a position in Gilead Sciences in Q4 2016 and held it in 1 quarter.
Heck Capital Advisors's Gilead Sciences position peaked at $78.3K in Q4 2016.
1,525 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2017.

Based on Heck Capital Advisors's 13F filing for Q1 2017, filed 19 May 2025.